Phase 2 Start
ONC: Phase 2 Start: A Phase 2 Study of Tislelizumab Administered With Alternative Dosing Schedules Plus Chemotherapy as
August 31, 2026 · tislelizumab. BioSniper AI can trace the company-impact path without requiring you to write the research question.
- Event date
- August 31, 2026
- Company
- BeOne Medicines Ltd. (ONC)
- Drug
- tislelizumab
BioSniper AIPage evidence connected
Prepared research question
What could this event change, and which evidence should be watched next?
Run cited research
Traceable citations · Unknowns marked
Phase 2 Start~month
Phase 2 Start: A Phase 2 Study of Tislelizumab Administered With Alternative Dosing Schedules Plus Chemotherapy as
- Company
- BeOne Medicines Ltd. (ONC)
- Drug
- tislelizumab
- Indication
- Metastatic Esophageal Squamous Cell Carcinoma; Advanced Esophageal Squamous Cell Carcinoma